IMPACT OF CARDIOLRX OVER 6 MONTHS FOLLOWING IL-1 BLOCKER CESSATION IN PERICARDITIS PATIENTS - MAVERIC-2. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Registry ID

CARDIOL 100-006

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CARDIOL THERAPEUTICS INC

Start date

2026-01-08

Last update

2024-11-19

Conditions

• PERICARDITIS

Related clinical trials

• A PHASE 2A, OPEN-LABEL PILOT STUDY TO EVALUATE THE SAFETY/TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VTX2735 IN PARTICIPANTS WITH RECURRENT PERICARDITIS
• A PHASE 2 POSOLOGY STUDY WITH LONG-TERM EXTENSION IN PARTICIPANTS WITH WELL CONTROLLED RECURRENT PERICARDITIS TO EVALUATE THE EFFICACY AND SAFETY OF TRANSITION REGIMENS TO KPL 387 MONOTHERAPY FROM STANDARD THERAPIES
• IDENTIFYING CLINICAL, SERUM, AND IMAGING BASED BIOMARKERS ASSOCIATED WITH HIGH-RISK PHENOTYPES FOR RECURRENT PERICARDITIS: A PROSPECTIVE COHORT STUDY

View on source registry